NCI-Supported Clinical Trials for Coronavirus

Clinical trials are research studies that involve people. Through clinical trials, doctors find new ways to improve treatments and the quality of life for people with disease.

NCI supports clinical trials to test promising treatments for patients with coronavirus disease 2019 (COVID-19) and to learn more about the disease's effects on the body. Some of the trials are specifically for patients with cancer. Your doctor can help you decide if a trial is right for you.

Trials 1-23 of 23
  • A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed / Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)

    The primary objective of this study is to evaluate the safety and tolerability of TAK-981 as a single agent in participants with advanced or metastatic solid tumors and lymphomas in dose escalation and cancer treatment expansions, and to assess change in acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load within 8 days of TAK-981 administration in COVID expansion.
    Location: 7 locations

  • Best Supportive Care with or without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 Infection

    This phase III trial compares best supportive care combined with low dose whole lung radiation therapy vs. best supportive care alone in treating patients with COVID-19 infection. Low-dose radiation therapy is a type of radiation treatment in which the total dose of radiation is less than that given in standard radiation therapy. The radiation dose used in this study is unlikely to cause short term side effects other than fatigue and temporary low blood cell count. The addition of low dose whole lung radiation therapy to best supportive care may improve patients' clinical status, the radiographic appearance of lungs and / or the laboratory blood tests.
    Location: 3 locations

  • A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

    This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a 2-part study comprising a Phase 1 safety lead-in (Part 1) that will determine the recommended TL-895 dose for Phase 2 (Part 2). In Part 1, TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. In Part 2, eligible subjects will be randomized in a 1:1 ratio to TL-895 with standard available treatment (SAT), or placebo with SAT. Investigators and Sponsor will be blinded to each subject's assigned study intervention throughout the course of the study.
    Location: 3 locations

  • PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

    This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • A Study of Hydroxychloroquine Compared to Placebo as Treatment for Patients with COVID-19

    This phase II trial studies how well hydroxychloroquine works in reducing the severity of symptoms in patients with coronavirus disease 2019 (COVID-19). Hydroxychloroquine is approved for the treatment of autoimmune diseases. An autoimmune disease is a condition in which the immune system mistakenly attacks the body. Researchers think that hydroxychloroquine may prevent the immune system from becoming overactive when it is fighting COVID-19. What is learned from this study may help doctors learn more about hydroxychloroquine as a treatment for COVID-19.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Tocilizumab for the Prevention of Respiratory Failure and Death in Patients with Severe COVID-19 Infection

    This phase II trial studies the effect of tocilizumab in preventing respiratory failure and death in patients with severe COVID-19 infection. Part of the complications from the COVID-19 infection may be due to the virus causing damage to the lungs, some of this damage may be caused by an extreme inflammatory reaction produced by the immune system as it tries to fight off the virus. A protein called IL-6 (interleukin 6) plays a major role in this type of inflammation. Tocilizumab may prevent IL-6 from attaching to cells. By blocking IL-6, tocilizumab may prevent damage to the lungs and reduce the need for treatment with a mechanical ventilator. If a patient is already receiving mechanical ventilation to assist with breathing, tocilizumab may improve the patient’s condition enough to allow this treatment to be stopped.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • A Study of N-acetylcysteine in Patients with COVID19 Infection

    This phase II trial identifies the effect of N-acetylcysteine in treating patients who have severe coronavirus disease-2019 (COVID-19) infection that does not respond to treatment (refractory) and are either patients in a critical care unit and / or are connected to a ventilator, or who are not in a critical care unit but require large amounts of supplemental oxygen. Recent studies suggest that the virus that causes COVID-19 may work by suppressing the immune system, which is the body's defense against infections and other diseases. White blood cells called lymphocytes are an important part of this defense, but recently it was found that the number of lymphocytes in a COVID-19 patient’s blood goes down as the infection gets worse and goes up as a patient gets better. N-acetylcysteine has been shown to help increase the number of lymphocytes in the blood when a virus is responsible for lowering it. This trial may help researchers determine whether N-acetylcysteine is effective enough against the virus that causes COVID-19 such that patients could leave the critical care unit or be taken off a ventilator, or could be prevented from needing ventilator support and management in a critical care unit.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients with Moderate and Severe COVID-19

    This phase II trial studies the effect of baricitinib in combination with antiviral therapy for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19). Treatment with antiviral medications such as hydroxychloroquine, lopinavir / ritonavir, and / or remdesivir may act against infection caused by the virus responsible for COVID-19. Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral therapy may reduce the risk of the disease from getting worse and may help prevent the need for being placed on a ventilator should the disease worsen compared to antiviral therapy alone.
    Location: 2 locations

  • Low-Dose Radiation Therapy for the Treatment of Storming Cytokines and Unchecked Edema in Patients with COVID-19 Infection, RESCUE 1-19 Study

    This phase I / II trial studies how well low-dose radiation therapy works in treating patients with SARS or pneumonia associated with COVID-19 infection. The purpose of this study is to investigate the use of selectively localized low-dose radiation therapy in reducing pulmonary immuno-toxicity (lung damage) within viral pneumonia infiltrates in critically-ill patients with SARS-COVID-19.
    Location: 2 locations

  • BMS-986253 for the Treatment of Hospitalized Patients with Severe COVID-19

    This phase II trial investigates how well BMS-986253 works in treating hospitalized patients with severe COVID-19. BMS-986253 may help to improve the health condition of patients infected with COVID-19.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection

    The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in participants with severe COVID-19 compared to placebo.
    Location: Wayne State University / Karmanos Cancer Institute, Detroit, Michigan

  • Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.

    CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Lopinavir / Ritonavir for the Treatment of COVID-19 Positive Patients with Cancer and Immune Suppression in the Last Year

    This phase II trial studies how well lopinavir / ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir / ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

    This phase Ib / II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Rintatolimod and IFN alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients

    This phase I / IIa trial studies the side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with mild or moderate COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients with SARS-CoV-2 Infection

    This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substances (cytokines) made by cells of the immune system as a response to SARS-CoV-2 infection. Tocilizumab may help lower the body’s immune response and reduce inflammation. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic

    This phase I trial investigates breathing techniques and meditation for health care workers during COVID-19 pandemic. Breathing techniques and medication may help manage stress and improve lung health. The goal of this trial is to learn if breathing techniques and meditation may help to reduce stress and improve lung health in health care workers during the COVID-19 pandemic.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study of Hydroxychloroquine versus Placebo to Prevent COVID-19 Infection in Patients Receiving Radiation Therapy

    This phase II trial studies how well hydroxychloroquine works in preventing infection with the COVID-19 virus in patients receiving radiation therapy. Hydroxychloroquine has been approved for the prevention and treatment of malaria, and the treatment of lupus and rheumatoid arthritis. Receiving radiation therapy may increase the risk of infection with the COVID-19 virus because the patients are in frequent and close contact with healthcare workers and with other patients who may have become infected. Patients receiving treatment for cancer may also have weakened immune system. Giving hydroxychloroquine may help prevent infection with SARS-CoV-2 in patients who are receiving radiation therapy for their cancer.
    Location: 7 locations

  • BCG Vaccine for Health Care Workers as Defense Against COVID 19

    SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported morbidity and mortality reductions as high as 70%. Furthermore, in our preliminary analysis, areas with existing BCG vaccination programs appear to have lower incidence and mortality from COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Remote COVID-19 Symptom Tracking and Improved Cancer Symptom Control for Cancer Patients at Home during the Pandemic

    This trial studies the use of an automated telehealth system, Symptom Care at Home (SCH), to assist with the care and monitoring of cancer symptoms and symptoms related to COVID-19 in cancer patients. The continued monitoring and care of cancer patients is important during a time when face-to-face contact is not advised due to a very contagious virus in the community. The SCH application may help improve communication by alerting cancer care providers about patients’ symptom concerns when the patient is at home. By doing this, providers may be able to care for patients remotely so they do not have to come into the clinics unless advised.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • NCI COVID-19 in Cancer Patients, NCCAPS Study

    This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
    Location: 709 locations

  • Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients with Breast Cancer Undergoing Breast Surgery

    This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). The goal of this study is to collect information about financial costs patients may have as a result of surgical treatment for cancer with or without breast reconstruction and to learn if COVID-19 affects patient costs of breast reconstruction. This may help researchers demonstrate the financial consequences of undergoing breast surgery.
    Location: 4 locations

  • Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection

    Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person s B and T cells respond to the virus. B and T cells are the major components of a person s immune response. B and T cells responding to the virus with a favorable pattern may lead to recovery, and this favorable pattern may be helpful to establish. If people in a vaccine trial get this same favorable pattern when responding to a vaccine, this may be a useful early signal that the vaccine will be successful. Objective: To examine how immune cells respond to COVID-19 infection. Eligibility: Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past. Also, healthy donors with no suspected COVID-19 infection Design: Participants will be screened with medical record review. Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. This test will be used to understand research results, not to advise patients. Participants with active infection must be isolated, usually in a hospital. Other participants may give blood samples at NIH or at their local doctor s office or lab. Participants may give blood samples up to three times a week for a total of ten times, and may also give blood samples after starting a vaccine trial. Participants will be contacted by phone or email every 2 months for up to 2 years.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland